Canaccord Genuity Reiterates a 'Buy' on Protalix BioTherapeutics (PLX); Q3/11: Tali NDA on Track, Cerezyme Shortage Continues
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.38 --0%
Rating Summary:
3 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
3 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Protalix BioTherapeutics (NYSE: PLX) price target of $8.00.
Canaccord analyst, Ritu Baral, said, "We see good chance of Feb’12 taliglucerase US approval, Q2/12 US launch and EU approval. We think PLX’s reply to the Feb‘11 taliglucerase (tali) CRL for Gaucher’s supports full approval on the new Feb’12 PDUFA date. We think tali may get ~15% of the $1.2B+ worldwide Gaucher’s market with competitive pricing."
For an analyst ratings summary and ratings history on Protalix BioTherapeutics click here. For more ratings news on Protalix BioTherapeutics click here.
Shares of Protalix BioTherapeutics closed at $6.40 yesterday.
Canaccord analyst, Ritu Baral, said, "We see good chance of Feb’12 taliglucerase US approval, Q2/12 US launch and EU approval. We think PLX’s reply to the Feb‘11 taliglucerase (tali) CRL for Gaucher’s supports full approval on the new Feb’12 PDUFA date. We think tali may get ~15% of the $1.2B+ worldwide Gaucher’s market with competitive pricing."
For an analyst ratings summary and ratings history on Protalix BioTherapeutics click here. For more ratings news on Protalix BioTherapeutics click here.
Shares of Protalix BioTherapeutics closed at $6.40 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
- Intchains Group Ltd (ICG) PT Lowered to $2 at Benchmark Following 1H Results
- Clear Street Reiterates Buy Rating on Anterix Inc. (ATEX)
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
